ASO Author Reflections: What are the Indications for Conversion Surgery for Initially Unresectable Pancreatic Cancer Who Received Modified FOLFIRINOX or Gemcitabine Plus Nab-paclitaxel? Is Surgery Really Worthwhile after Sufficient Chemotherapy?

被引：1
|
作者：
Ushida, Yuta [1 ]
Inoue, Yosuke [1 ]
Oba, Atsushi [1 ]
Mie, Takafumi [1 ]
Ito, Hiromichi [1 ]
Ono, Yoshihiro [1 ]
Sato, Takafumi [1 ]
Ozaka, Masato [1 ]
Sasaki, Takashi [1 ]
Saiura, Akio [1 ,2 ]
Sasahira, Naoki [1 ]
Takahashi, Yu [1 ]
机构：
[1] Japanese Fdn Canc Res, Canc Inst Hosp, Dept Gastroenterol Surg, Tokyo, Japan
[2] Juntendo Univ Hosp, Dept Hepatobiliary Pancreat Surg, Tokyo, Japan
来源：
ANNALS OF SURGICAL ONCOLOGY | 2022年 / 29卷 / 08期
关键词：
D O I：
10.1245/s10434-022-11621-1
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：5051 / 5052
页数：2
相关论文
共 48 条
  • [41] Prognostic factors in conversion surgery following nab-paclitaxel with gemcitabine and subsequent chemoradiotherapy for unresectable locally advanced pancreatic cancer: Results of a dual-center study
    Igarashi, Takamichi
    Yamada, Suguru
    Hoshino, Yui
    Murotani, Kenta
    Baba, Hayato
    Takami, Hideki
    Yoshioka, Isaku
    Shibuya, Kazuto
    Kodera, Yasuhiro
    Fujii, Tsutomu
    ANNALS OF GASTROENTEROLOGICAL SURGERY, 2023, 7 (01): : 157 - 166
  • [42] Early detection of venous thromboembolism after the initiation of chemotherapy predicts a poor prognosis in patients with unresectable metastatic pancreatic cancer who underwent first-line chemotherapy with gemcitabine plus nab-paclitaxel
    Yamai, Takuo
    Ikezawa, Kenji
    Hiraga, Erika
    Kawamoto, Yasuharu
    Hirao, Takeru
    Higashi, Sena
    Daiku, Kazuma
    Maeda, Shingo
    Abe, Yutaro
    Urabe, Makiko
    Kai, Yugo
    Takada, Ryoji
    Nakabori, Tasuku
    Fukutake, Nobuyasu
    Uehara, Hiroyuki
    Fujita, Masashi
    Ohkawa, Kazuyoshi
    PLOS ONE, 2022, 17 (03):
  • [43] Successful conversion surgery for unresectable pancreatic cancer with peritoneal metastases after neoadjuvant albumin-bound paclitaxel and gemcitabine chemotherapy: case report and literature review
    Yuta Kobayashi
    Sakae Maeda
    Naoki Hama
    Atsushi Miyamoto
    Mamoru Uemura
    Masakazu Miyake
    Kazuhiro Nishikawa
    Motohiro Hirao
    Takeshi Kato
    Mitsugu Sekimoto
    Kiyoshi Mori
    Masayuki Mano
    Shoji Nakamori
    International Cancer Conference Journal, 2018, 7 (1) : 20 - 25
  • [44] Successful conversion surgery for unresectable pancreatic cancer with peritoneal metastases after neoadjuvant albumin-bound paclitaxel and gemcitabine chemotherapy: case report and literature review
    Kobayashi, Yuta
    Maeda, Sakae
    Hama, Naoki
    Miyamoto, Atsushi
    Uemura, Mamoru
    Miyake, Masakazu
    Nishikawa, Kazuhiro
    Hirao, Motohiro
    Kato, Takeshi
    Sekimoto, Mitsugu
    Mori, Kiyoshi
    Mano, Masayuki
    Nakamori, Shoji
    INTERNATIONAL CANCER CONFERENCE JOURNAL, 2018, 7 (01): : 20 - 25
  • [45] Conversion rate in locally advanced pancreatic cancer (LAPC) after nab-paclitaxel/gemcitabine- or FOLFIRINOX-based induction chemotherapy (NEOLAP): Final results of a multicenter randomised phase II AIO trial
    Kunzmann, V.
    Alguel, H.
    Goekkurt, E.
    Siegler, G. M.
    Martens, U. M.
    Waldschmidt, D.
    Pelzer, U.
    Hennes, E.
    Fuchs, M.
    Siveke, J.
    Kullmann, F.
    Boeck, S.
    Ettrich, T. J.
    Ferenczy, P.
    Keller, R.
    Germer, C-T.
    Stein, H.
    Hartlapp, I.
    Klein, I.
    Heinemann, V.
    ANNALS OF ONCOLOGY, 2019, 30 : 253 - 253
  • [46] Naive indirect treatment comparison of PanCO, a pilot study of OncoSil P-32 microparticles combined with gemcitabine plus nab-paclitaxel or FOLFIRINOX chemotherapy versus standard-of-care treatment in unresectable locally advanced pancreatic cancer
    Allerdice, S.
    Wilson, N.
    Turner, D.
    McCloud, P.
    Kenny, D.
    Cowley, A.
    Taylor, C.
    ANNALS OF ONCOLOGY, 2020, 31 : S174 - S175
  • [47] Early tumor shrinkage as a prognostic predictor in chemotherapy-naïve patients with locally advanced pancreatic cancer treated with modified FOLFIRINOX or gemcitabine plus nab-paclitaxel combination therapy: An exploratory analysis of JCOG1407
    Tezuka, Shun
    Ozaka, Masato
    Furuse, Junji
    Yokoyama, Masayuki
    Uemura, Kohei
    Sano, Yusuke
    Nakachi, Kohei
    Imaoka, Hiroshi
    Unno, Michiaki
    Shirakawa, Hirofumi
    Shimizu, Satoshi
    Kato, Naoya
    Kojima, Yasushi
    Sano, Keiji
    Kobayashi, Satoshi
    Terashima, Takeshi
    Morizane, Chigusa
    Ikeda, Masafumi
    Ueno, Makoto
    PANCREATOLOGY, 2024, 24 (06) : 909 - 916
  • [48] ASO Author Reflections: The Gustave Roussy Immune Score May Be a Useful Biomarker for Conversion Surgery After Chemotherapy Plus Nivolumab as the First-Line Treatment for Gastric Cancer
    Nakazawa, Nobuhiro
    Sano, Akihiko
    Sakai, Makoto
    Shirabe, Ken
    Saeki, Hiroshi
    ANNALS OF SURGICAL ONCOLOGY, 2024, 31 (13) : 9052 - 9053
12345